The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Overview

Información sobre este estudio

The purpose of this study is to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials.  

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Patients must be less than 22 years of age at the time of study enrollment.

- Patient must have one of the following:

- Patient has known or suspected relapsed/refractory (including primary refractory) AML;

- This includes isolated myeloid sarcoma.

- Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome.

- Patient has known or suspected relapsed ALL that meets one of the following criteria:

- Second or greater B-ALL medullary relapse, excluding KMT2Ar;

- Any first or greater B-ALL medullary relapse involving KMT2Ar;

- Any first or greater T-ALL medullary relapse with or without KMT2Ar;

- Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia;

- Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment related AML.

- All patients and/or their parents or legal guardians must sign a written informed consent.

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/4/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Wendy Allen-Rhoades, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20540751

Mayo Clinic Footer